The endpoints were categorized as follows: 43 endpoints evaluated recent efficacy, 23 endpoints described clinical symptomatic efficacy, 24 endpoints described Karnofsky Performance Status (KPS) scores, 23 endpoints analyzed leukopenia, 15 endpoints examined thrombocytopenia, 26 endpoints investigated gastrointestinal reactions, 10 endpoints reported CD3+ conditions, 12 endpoints described CD4+ conditions, 9 endpoints evaluated CD8+ cell status, and 13 endpoints assessed CD4+/CD8+ ratios. The gene discussed is CD4; the disease is Decreased total leukocyte count.